Ruffer LLP Purchases Shares of 75,501 Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

Ruffer LLP purchased a new stake in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 75,501 shares of the company's stock, valued at approximately $2,598,000. Ruffer LLP owned 0.13% of Harmony Biosciences as of its most recent filing with the SEC.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. GAMMA Investing LLC lifted its holdings in Harmony Biosciences by 92.6% in the 4th quarter. GAMMA Investing LLC now owns 907 shares of the company's stock valued at $31,000 after purchasing an additional 436 shares in the last quarter. PNC Financial Services Group Inc. raised its holdings in shares of Harmony Biosciences by 28.7% during the 4th quarter. PNC Financial Services Group Inc. now owns 2,328 shares of the company's stock worth $80,000 after acquiring an additional 519 shares during the period. New York State Teachers Retirement System raised its holdings in shares of Harmony Biosciences by 2.6% during the 4th quarter. New York State Teachers Retirement System now owns 31,693 shares of the company's stock worth $1,091,000 after acquiring an additional 809 shares during the period. KBC Group NV raised its holdings in shares of Harmony Biosciences by 79.9% during the 4th quarter. KBC Group NV now owns 1,844 shares of the company's stock worth $63,000 after acquiring an additional 819 shares during the period. Finally, Hedeker Wealth LLC raised its holdings in shares of Harmony Biosciences by 1.2% during the 4th quarter. Hedeker Wealth LLC now owns 76,203 shares of the company's stock worth $2,622,000 after acquiring an additional 916 shares during the period. Institutional investors and hedge funds own 86.23% of the company's stock.

Remove Ads

Harmony Biosciences Stock Performance

Shares of Harmony Biosciences stock traded down $0.88 during trading hours on Thursday, hitting $32.72. 399,182 shares of the company were exchanged, compared to its average volume of 634,600. Harmony Biosciences Holdings, Inc. has a 1 year low of $28.14 and a 1 year high of $41.61. The company has a current ratio of 3.24, a quick ratio of 3.20 and a debt-to-equity ratio of 0.28. The business has a 50-day moving average of $36.48 and a 200-day moving average of $35.67. The stock has a market capitalization of $1.88 billion, a price-to-earnings ratio of 15.51, a P/E/G ratio of 0.47 and a beta of 0.82.

Harmony Biosciences (NASDAQ:HRMY - Get Free Report) last announced its quarterly earnings data on Tuesday, February 25th. The company reported $0.85 earnings per share for the quarter, topping analysts' consensus estimates of $0.74 by $0.11. Harmony Biosciences had a return on equity of 23.16% and a net margin of 17.98%. The firm had revenue of $201.30 million for the quarter, compared to analyst estimates of $201.25 million. During the same quarter in the prior year, the company posted $0.45 earnings per share. Harmony Biosciences's quarterly revenue was up 19.5% on a year-over-year basis. As a group, analysts expect that Harmony Biosciences Holdings, Inc. will post 2.43 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the company. Mizuho reduced their price target on Harmony Biosciences from $52.00 to $42.00 and set an "outperform" rating on the stock in a report on Thursday, February 20th. HC Wainwright dropped their target price on Harmony Biosciences from $75.00 to $70.00 and set a "buy" rating for the company in a research report on Thursday, February 27th. Deutsche Bank Aktiengesellschaft assumed coverage on Harmony Biosciences in a research report on Tuesday, February 11th. They set a "buy" rating and a $55.00 price objective for the company. Finally, Needham & Company LLC reissued a "buy" rating and set a $50.00 price objective on shares of Harmony Biosciences in a research report on Tuesday, February 25th. Nine investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Harmony Biosciences currently has a consensus rating of "Buy" and a consensus price target of $53.11.

Insider Buying and Selling

In other Harmony Biosciences news, insider Jeffrey Dierks sold 1,123 shares of the company's stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $40.00, for a total value of $44,920.00. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Jeffrey M. Dayno sold 19,293 shares of the company's stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $40.13, for a total value of $774,228.09. The disclosure for this sale can be found here. Insiders have sold 72,452 shares of company stock valued at $2,831,679 over the last quarter. Company insiders own 30.80% of the company's stock.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.